Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Allianz Asset Management GmbH

Allianz Asset Management GmbH boosted its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 453.9% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 325,403 shares of the specialty pharmaceutical company’s stock after buying an additional 266,658 shares during the period. Allianz Asset Management GmbH owned 0.54% of Jazz Pharmaceuticals worth $34,532,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of JAZZ. Hurley Capital LLC acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at about $25,000. Picton Mahoney Asset Management lifted its stake in shares of Jazz Pharmaceuticals by 2,445.5% in the 1st quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 269 shares in the last quarter. Spire Wealth Management lifted its stake in shares of Jazz Pharmaceuticals by 137.6% in the 1st quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company’s stock valued at $35,000 after purchasing an additional 161 shares in the last quarter. SVB Wealth LLC acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at about $36,000. Finally, Geneos Wealth Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $136.06 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06. The stock’s 50 day moving average is $128.20 and its two-hundred day moving average is $116.00. The company has a market capitalization of $8.25 billion, a PE ratio of -20.22, a P/E/G ratio of 8.35 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.05 billion. During the same quarter in the prior year, the firm earned $5.30 earnings per share. Jazz Pharmaceuticals’s revenue for the quarter was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 3,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total transaction of $490,000.00. Following the sale, the director directly owned 408,826 shares in the company, valued at $57,235,640. The trade was a 0.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on JAZZ shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Royal Bank Of Canada lifted their price objective on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an “outperform” rating in a research note on Thursday, August 28th. Zacks Research upgraded Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, October 8th. Finally, Morgan Stanley raised their target price on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the company an “overweight” rating in a report on Wednesday, September 24th. Fourteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $178.93.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.